Jinesh Mehta, MD
Pulmonary Disease · Weston, FLNPI 1619918232
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,518 of the $38,276 with a category attached, or 74.5%. United Therapeutics Corporation accounts for 79.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $15,836 and has fallen 99.3% since, to $114 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $394.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$30K
- Grifols USA, LLC$3K
- Bayer$2K
- Nabriva Therapeutics, PLC$2K
- Actelion Pharmaceuticals US, Inc.$308
- GSK$247
- plus $453 from 11 others
Across 180 payments — averaging $3371.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$594K
- Janssen Research & Development, LLC$13K
What the payments were for
- Consulting fees$5,67315%
- Speaking & faculty fees$28,51875%
- Travel & lodging$1,8075%
- Food & beverage$2,2726%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 43 | $30,373 |
| Grifols USA, LLC | 6 | $2,681 |
| Bayer | 4 | $2,424 |
| Nabriva Therapeutics, PLC | 2 | $1,790 |
| Actelion Pharmaceuticals US, Inc. | 7 | $308 |
| GSK | 14 | $247 |
| Boehringer Ingelheim | 4 | $92 |
| Genentech USA, Inc. | 4 | $74 |
| Intuitive Surgical | 1 | $65 |
| Boston Scientific | 3 | $53 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| Lungpacer Medical USA Inc | 1 | $31 |
| Sandoz | 2 | $27 |
| AstraZeneca | 1 | $22 |
| Ambu Inc. | 1 | $18 |
| Covidien LP | 1 | $17 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,276 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 148 | $3,036,013 |
| AdempasRiociguat | 140 | $2,022,692 |
| OpsumitMacitentan | 138 | $1,740,374 |
| Orenitram ErTreprostinil Diolamine | 85 | $801,606 |
| Tyvaso DpiTreprostinil | 33 | $710,969 |
| OfevNintedanib Esylate | 45 | $600,852 |
| Ambrisentan | 140 | $352,343 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 295 | $247,472 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 131 | $75,231 |
| Tadalafil | 105 | $47,269 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $44,823 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $39,603 |
| Sildenafil Citrate | 159 | $36,721 |
| SymbicortBudesonide/Formoterol Fumarate | 91 | $32,037 |
| Spiriva RespimatTiotropium Bromide | 24 | $28,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $308 | $4,776,388286 claims |
| BayerAdempas | $2,424 | $2,022,692140 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $92 | $668,616135 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $247 | $347,374473 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $22 | $76,860159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Weston
- Franck RahaghiWeston$1.2M
- Anas HadehWeston$800K
- David ZismanWeston$112K
- Roger AlvarezWeston$82K
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.